https://clinicaltrials.gov/ct2/show/NCT04091360?type=Intr&cond=COPD&sfpd_d=14&sel_rss=new14 A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease Condition : COPD Interventions : Drug: Ensifentrine 100mcg; Drug: Ensifentrine 300mcg; Drug: Ensifentrine 1000mcg; Drug: Ensifentrine 3000mcg; Drug: Ensifentrine 6000mcg; Drug: Placebos Sponsors : Verona Pharma plc; Iqvia Pty Ltd Recruiting NCT04091360 Mon, 16 Sep 2019 12:00:00 EDT
RPL554
Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine (RPL554) in COPD at CHEST 2019
http://www.globenewswire.com/news-release/2019/10/15/1929421/0/en/Verona-Pharma-to-Present-Phase-2-Symptom-Data-with-Ensifentrine-in-COPD-at-CHEST-2019.html Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019
Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD
https://www.ncbi.nlm.nih.gov/pubmed/31474120?dopt=Abstract https://www.ncbi.nlm.nih.gov/pubmed/31474120?dopt=Abstract Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. Related Articles Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. Expert Opin Investig Drugs. 2019 Sep 01;:1-7 Authors: Cazzola M, Calzetta L, Rogliani P, Matera MG Abstract Introduction: A compound that simultaneously inhibits PDE3 and PDE4 should increase airway […]
The Effects of RPL554 in Addition to Tiotropium in COPD Patients [Completed]
https://clinicaltrials.gov/ct2/show/NCT03028142?type=Intr https://clinicaltrials.gov/ct2/show/NCT03028142?type=Intr&cond=COPD&phase=01234&lupd_s=01%2F09%2F2019&lupd_d=14&sort=nwst The Effects of RPL554 in Addition to Tiotropium in COPD Patients Condition : Chronic Obstructive Pulmonary Disease Moderate Interventions : Drug: 1.5 mg RPL554 plus tiotropium; Drug: 6 mg RPL554 plus tiotropium; Drug: Placebo plus tiotropium Sponsor : Verona Pharma plc Completed NCT03028142 Mon, 23 Jan 2017 12:00:00 EST